FDA Panel Divided on Unproven Peptide Safety

Health advisers convened this week for a two-day meeting hosted by the Food and Drug Administration to examine more than a half-dozen peptides. These substances have surged in popularity as a wellness trend, fueled by testimonials on social media from influencers and podcasters who claim they aid in muscle building, injury recovery, and anti-aging. However, this support stands in contrast to the FDA's career scientists, who have voiced concerns regarding the limited data available on their safety and efficacy.

The panel of outside advisers includes individuals with financial ties to the peptide industry, such as owners of wellness clinics and pharmacies that produce peptide formulas. This has drawn criticism, echoing concerns from previous expert panels. FDA scientists have reiterated their long-standing apprehension, noting that most available data comes from animal studies, not humans. They recommend against allowing seven popular peptides, including BPC-157 and TB-500, to be compounded by pharmacies, citing risks of contamination, allergic reactions, and quality control issues.

Despite the FDA's stance, peptide supporters are urging the agency to ease access, with groups like the American Academy of Peptide Medicine highlighting their benefits for patients. The FDA received over 1,900 public comments on the matter. Following the meeting, the FDA will consider the votes, discussions, and public feedback before making a final decision on whether to expand access to these peptides.